Skip to search formSkip to main contentSkip to account menu

ezlopitant

Known as: (2S,3S)-2-(Diphenylmethyl)-3-((5-isopropyl-2-methoxybenzyl)amino)quinuclidine, (2S,3S,4S)-2-diphenylmethyl-3-(5-isopropyl-2-methoxybenzylamino)-1-azabicyclo(2.2.2)octane, (2S,3S)-2-(Diphenylmethyl)-3-((5-isopropyl-2-methoxy- benzyl)amino)quinuclidine 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (2)

BenzylaminesBridged Bicyclo Compounds, Heterocyclic

Narrower (1)

CJ 11974

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2013
Highly Cited
2013
A Perspective on the Prediction of Drug Pharmacokinetics and Disposition in Drug Research and Development
Prediction of human pharmacokinetics of new drugs, as well as other disposition attributes, has become a routine practice in drug… 
2010
2010
The Neurokinin 1 Receptor Antagonist, Ezlopitant, Reduces Appetitive Responding for Sucrose and Ethanol
Background The current obesity epidemic is thought to be partly driven by over-consumption of sugar-sweetened diets and soft… 
Review
2004
Review
2004
The Role of Tachykinins and the Tachykinin NK1 Receptor in Nausea and Emesis
Nausea and vomiting are both components of the body’s defensive system to protect against the effects of accidentally ingested… 
Highly Cited
2003
Highly Cited
2003
Impact of nonspecific binding to microsomes and phospholipid on the inhibition of cytochrome P4502D6: implications for relating in vitro inhibition data to in vivo drug interactions.
The effects of microsomal concentration on the inhibitory potencies of four compounds--fluoxetine, quinidine, imipramine, and… 
2002
2002
Anti-Emetic Activity of the Novel Nonpeptide Tachykinin NK1 Receptor Antagonist Ezlopitant (CJ-11,974) against Acute and Delayed Cisplatin-Induced Emesis in the Ferret
The anti-emetic effects of a novel tachykinin NK1 receptor antagonist, ezlopitant ((2S,3S-cis)-2-diphenylmethyl)- N--1-azabicyclo… 
Review
2002
Review
2002
Irritable bowel syndrome neuropharmacology. A review of approved and investigational compounds.
Anticholinergics and prokinetics are mainstays of therapy for Irritable Bowel Syndrome (IBS) patients despite their limited… 
2001
2001
Mechanism of cytochrome P4503A4- and 2D6-catalyzed dehydrogenation of ezlopitant as probed with isotope effects using five deuterated analogs.
Ezlopitant is metabolized by cytochrome P450 primarily to two metabolites: a benzyl alcohol and a corresponding alkene. The… 
2001
2001
Cytochrome P450-catalyzed metabolism of ezlopitant alkene (CJ-12,458), a pharmacologically active metabolite of ezlopitant: enzyme kinetics and mechanism of an alkene hydration reaction.
Experiments were conducted to characterize the metabolism of ezlopitant alkene (CJ-12,458), an active metabolite of ezlopitant… 
2000
2000
Metabolism of ezlopitant, a nonpeptidic substance P receptor antagonist, in liver microsomes: enzyme kinetics, cytochrome P450 isoform identity, and in vitro-in vivo correlation.
The enzyme kinetics of the metabolism of ezlopitant in liver microsomes from various species have been determined. The rank order… 
Review
2000
Review
2000
Potential of Substance P Antagonists as Antiemetics
The introduction of serotonin 5-HT3 receptor antagonists into clinical practice allowed for a dramatic improvement in the… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)